Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy
Study to determine response rate of the combination of pembrolizumab plus epacadostat in patients with head and neck cancers that have received prior immunotherapy.
Head and Neck Squamous Cell Carcinoma|Head and Neck Cancer
DRUG: Pembrolizumab|DRUG: Epacadostat
Response Rate, Rate of clinical disease response (tumor shrinkage) as seen on imaging., up to 18 months
Progression Free Survival, Number of patients that have not had disease worsening across both study groups., 1 year|Overall Survival, Number of patients surviving across both study groups., 1 year|Side Effects, Number of patients with side effect. Summary of side effects by type is provided in adverse events section below., 6 months
Study to determine response rate of the combination of pembrolizumab plus epacadostat in patients with head and neck cancers that have received prior immunotherapy.